Ignite Creation Date:
2024-05-06 @ 7:06 PM
Last Modification Date:
2024-10-26 @ 3:00 PM
Study NCT ID:
NCT05892042
Status:
RECRUITING
Last Update Posted:
2023-06-07
First Post:
2023-05-28
Brief Title:
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
Sponsor:
Jilin University
Organization:
Jilin University
Study Overview
Official Title:
Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACTonLVT
Brief Summary:
Contemporary data are lacking regarding the management of left ventricular thrombus LVT developed after ST segment elevation myocardial infarction
Detailed Description:
Left ventricular thrombus LVT is a commom complication after ST segment elevation myocardial infarction STEMI reperfusion therapy have reduced the incidence of LVT however about 6 of all STEMI patients will develop LVT the risk of LVT development in anterior STEMI with reduced LVEF are as high as 20 Although current guideline recommend anti-coagulation therapy but the evidence still based on observational data there has been inconsistency with the benefit of the coagulation therapy give the significant increased bleeding risk by superimpose anti-coagulation therapy to the dual anti-platelet therapy especially in the era of more potent anti-platelet P2Y12 inhibitor widely used clinical the mechanism of LVT is different from that of the atrial fibrillation in which the risk of systemic embolism is persistent coagulation bring absolute clinical benefit for high risk patients however for LVT developed following STEMI tend to be temporary majority of thrombus resolve within 1-3 months after STEMI event more likely a reflection of coagulation system in response to the necrosis of infarct myocardium The optimal management in LVT after STEMI warrants further exploration the desiring of randomized controlled clinical trial to compare dual anti platelet anti-coagulation and dual anti-platelet without anti-coagulation in patient LVT are justified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None